Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Emblaveo is a fixed-dose IV treatment that combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Constipation is a common issue affecting millions. A gastroenterologist shares effective strategies to ease this discomfort, ...